文献速递白血病淋巴瘤

T细胞幼淋巴细胞白血病患者临床病程、结局及预后因素的界定

Delineation of clinical course, outcomes, and prognostic factors in patients with T-cell prolymphocytic leukemia.
PubMed 文献 · Am J Hematol · 2023-04-03

该研究回顾性分析了81例在本中心治疗的T细胞幼淋巴细胞白血病(T-PLL)患者,比较初始表现为相对惰性或稳定病程者与侵袭性病程者的临床病理特征、总生存(OS)及预后因素。惰性疾病患者OS显著长于活动性疾病患者;诊断时B症状、低血红蛋白、低血小板计数、淋巴细胞倍增时间少于3个月及异常细胞遗传学与较短OS相关。一线使用阿仑单抗及异基因造血干细胞移植巩固与更好结局相关。

要点

  • 惰性疾病患者的总生存期显著长于活动性疾病患者。
  • 诊断时B症状、低血红蛋白、低血小板计数、淋巴细胞倍增时间少于3个月及异常细胞遗传学与较短OS相关。
  • 一线使用阿仑单抗及异基因造血干细胞移植巩固与更好结局相关。

核心结论

  • T-PLL惰性与活动性疾病亚型可表现出重叠但不同的临床和病理特征。
  • 描述了若干诊断时的预后因素,可用于风险分层并帮助指导治疗决策。

研究设计与样本

  • 回顾性分析了81例在本中心治疗的T-PLL患者。
  • 比较了初始表现为相对惰性或稳定病程的患者与侵袭性病程患者。
  • 分析了临床病理特征、总生存(OS)及预后因素。

主要发现

  • 惰性疾病患者的总生存期显著长于活动性疾病患者。
  • 诊断时存在B症状、低血红蛋白、低血小板计数、淋巴细胞倍增时间少于3个月及异常细胞遗传学与较短OS相关。
  • 细胞形态、免疫表型、绝对淋巴细胞计数、乳酸脱氢酶水平、肝、脾、皮肤或中枢神经系统受累、TCL1重排或inv(14)/t(14;14)、8号染色体异常及11q缺失与患者间显著OS差异无关。
  • 一线接受阿仑单抗治疗及异基因造血干细胞移植巩固与更好结局相关。

临床怎么用

  • 作者描述了若干诊断时的预后因素,可用于风险分层并帮助指导治疗决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

T-cell prolymphocytic leukemia (T-PLL) is a rare, post-thymic T-cell neoplasm with a diverse clinical course. T-PLL is typically associated with a poor prognosis; however, a subset of patients have inactive disease on initial presentation. There is a lack of accurate delineation of the disease based on initial clinical presentation and pathological assessment, hindering clinical decision-making. To characterize and delineate disease subtypes based on initial clinical presentation and pathologic assessment, we retrospectively reviewed 81 patients with T-PLL treated at our institution. We compared patients with T-PLL who initially presented with a relatively indolent or stable disease course to those with an aggressive disease course. Clinicopathologic characteristics, overall survival (OS), and prognostic factors were analyzed. Patients with inactive disease had a significantly longer OS than patients with active disease. At diagnosis, presence of B symptoms, low hemoglobin, low platelet count, lymphocyte doubling time of fewer than 3 months, and abnormal cytogenetics were associated with shorter OS. Cell morphology, immunophenotype, absolute lymphocyte count, lactate dehydrogenase levels, involvement of liver, spleen, skin or central nervous system, presence of TCL1 rearrangement or inv (14)/t(14;14), presence of chromosome 8 abnormalities, and presence of deletion of 11q were not associated with significant OS difference among the patients. Receiving alemtuzumab as first-line treatment and consolidation with allogeneic hematopoietic stem cell transplant were associated with better outcomes. T-PLL inactive and active disease subtypes can exhibit overlapping yet different clinical and pathological features. We describe several prognostic factors at diagnosis that can be used for risk stratification and aid in guiding treatment decisions.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Rose A, Zhang L, Jain AG, et al. Delineation of clinical course, outcomes, and prognostic factors in patients with T-cell prolymphocytic leukemia. Am J Hematol. 2023. PMID: 36964941. doi:10.1002/ajh.26918

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。